Logo

BMS & Exelixis Present Two Years Follow-Up Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) in P-III (CheckMate -9ER) Trial for RCC at ASCO 2022

Share this

BMS & Exelixis Present Two Years Follow-Up Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) in P-III (CheckMate -9ER) Trial for RCC at ASCO 2022

Shots:

  • The P-III (CheckMate -9ER) trial evaluates Opdivo + Cabometyx vs sunitinib in 651 patients with RCC. The trial is sponsored by BMS & Ono & co-funded by Exelixis, Ipsen & Takeda
  • The results showed sustained efficacy benefits & response rate along with HRQoL improvements in a separate analysis with a median follow-up of 32.9mos., no new safety signals were observed, improvements in m-OS (37.7mos. vs 34.3mos.) with 30% reduction in risk of death, m-PFS (16.6mos. vs 8.3mos.)
  • Additonally, ORR (55.7% vs 28.4%), m-DoR (23.1mos. vs 15.1mos.), CR rate (12.4% vs 5.2%), patients experienced TRAE (97.2% vs 93.1%) along with tumor shrinkage benefits, (65.0% vs 54.1%) had a grade ≥3 TRAE

 Ref: Exelixis | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions